Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | RAPGEF4 | Q8WZA2 | 6/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1936771 | 0.82 | MEN1 (0.43) | F2PRSS1PRSS2PRSS3MAPT | |
| SCHEMBL957952 | 0.82 | MEN1 (0.43) | F2PRSS1PRSS2PRSS3MAPT | |
| SCHEMBL187717 | 0.82 | MEN1 (0.43) | F2PRSS1PRSS2PRSS3MAPT | |
| SCHEMBL28872882 | 0.79 | RAPGEF4 (0.47) | F2PRSS1PRSS2PRSS3MAPT | |
| SCHEMBL29488823 | 0.77 | F2 (0.38) | F2PRSS1PRSS2PRSS3MAPT | |
| SCHEMBL22767840 | 0.77 | F2 (0.43) | F2PRSS1PRSS2PRSS3MAPT | |
| SCHEMBL25440241 | 0.75 | MAPT (0.37) | F2PRSS1PRSS2PRSS3MAPT | |
| SCHEMBL25843755 | 0.75 | MEN1 (0.40) | F2PRSS1PRSS2PRSS3MAPT | |
| SCHEMBL20638381 | 0.74 | MEN1 (0.39) | F2PRSS1PRSS2PRSS3MAPT | |
| SCHEMBL2678329 | 0.73 | CA1 (0.50) | F2PRSS1PRSS2PRSS3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109294200-A | A kind of preparation method of laminated silicate clay nano Composite polycarbonate material | 宁波高新区诠宝绶新材料科技有限公司 | 2019-02-01 | — | — | CN | claimed |
| CN-108951277-A | A kind of preparation method of paper grade (stock) anti-biotic material | 孝感寰誉新材科技有限公司 | 2018-12-07 | — | — | CN | claimed |
| CN-109294200-A | A kind of preparation method of laminated silicate clay nano Composite polycarbonate material | 宁波高新区诠宝绶新材料科技有限公司 | 2019-02-01 | — | — | CN | disclosed |
| CN-108951277-A | A kind of preparation method of paper grade (stock) anti-biotic material | 孝感寰誉新材科技有限公司 | 2018-12-07 | — | — | CN | disclosed |
| US-20180111933-A1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-26 | — | — | US | disclosed |
| US-20180111942-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-26 | — | — | US | disclosed |
| US-7579340-B2 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | PFIZER INC (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070293503-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7288538-B2 | Cardiovascular homeostasis through combination of direct neuronal control and systemic neurohormonal activation | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20050049286-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049286-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | F2 3969/4885PRSS1 304/4885PRSS2 191/4885 |
| US-20180111942-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN3A, GRIN1, GRIN2B | F2 4753/4885PRSS1 4567/4885PRSS2 4602/4885 |
| US-20180111933-A1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN3A, GRM1 | F2 3615/4885PRSS1 4011/4885PRSS2 4475/4885 |
| US-20070293503-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | F2 3969/4885PRSS1 304/4885PRSS2 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.